Lonza Group Ltd Announces Stefan Stoffel to Executive Committee
February 25, 2019 at 01:00 am
Share
Lonza Group Ltd. announced that Stefan Stoffel has been appointed to a new role on the Executive Committee as COO, Lonza Pharma Biotech & Nutrition (LPBN), responsible for operations, from 1 March, 2019. In his newly created position, Stefan Stoffel will cover Operations, Quality, Engineering and Strategic Growth Initiatives across the LPBN segment. Stefan will join Marc Funk (incoming CEO), Sven Abend (COO LSI) and Rodolfo Savitzky (CFO) on the Executive Committee. The commercial functions of the new LPBN segment will be driven by Marc Funk for the time being.
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (13.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.8%).
Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).